Interview with Sir Andrew Dillon, Chief Executive, National Institute for Health…
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
Address: National Institute for Health and Clinical Excellence
1st Floor
10 Spring Gardens
London
SW1A 2BU
Tel: +44 (0)845 003 7780
The National Institute for Health and Clinical Excellence (NICE) is an NHS organisation based in London and Manchester. NICE was set up on 1 April 1999 to ensure everyone has equal access to medical treatments and high quality care from the NHS – regardless of where they live in England and Wales.
Today NICE is recognised as being a world leader in setting standards for high quality healthcare and are the most prolific producer of clinical guidelines in the world. It also produces public health recommendations on how to help improve people’s health and prevent disease. These are aimed not just at the NHS but at local authorities and all those with a remit for improving people’s health in the public, private, community and voluntary sectors.
Topics covered by NICE’ guidance range from helping people to stop smoking and encouraging them to be more physically active through to the treatment of cancer, diabetes, musculoskeletal conditions and mental health problems. NICE also makes recommendations on the use of a range of drugs.
All its recommendations are devised by independent committees. NICE’s Citizens Council is the UK’s first advisory body made up entirely of members of the public.
NICE is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health.
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
Airfinity’s Dr Patricia Gallego highlights the persistent threat that COVID-19 continues to present to patients and healthcare systems around the world and outlines the urgent need for more vaccine breakthroughs…
The UK government has decided to go ahead with a much-debated increase in the revenue clawback rate —from 24.4 percent to 27.5 percent— for drugmakers subject to its Statutory Scheme…
Dr Matt Linley, senior director for analytics and forecasting at predictive health analytics firm Airfinity, looks ahead to a potentially game-changing year in the fight against respiratory synctial virus (RSV),…
A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding…
What digital skills do pharma leaders need in order to drive transformation, deliver success at scale in the business, and prepare for next-gen customer engagement? Sarah Gilchriest explores the critical…
Bernard Ross, a serial entrepreneur with more than 20 years’ senior experience at private and public board level across multiple industries, looks ahead to 2023 and highlights five key trends…
After an almost 20-year career in Big Pharma culminating in a role as president of AstraZeneca UK, Lisa Anson took the leap into the biotech world to lead what at…
Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical…
National Health Service (NHS) England CEO Amanda Pritchard has raised concerns about the state of British healthcare in recent weeks and months, proclaiming that the NHS is in a worse…
With the brief tenure of Liz Truss as Prime Minister already drawing to a close, the UK faces yet another new leader as the country attempts to extricate itself from…
“Life sciences are at the heart of my vision to build a country fit for the future,” tweeted new UK Prime Minister Liz Truss last month. Now installed as leader…
US biotech Moderna – producer of a messenger RNA (mRNA) COVID-19 vaccine that has found its way into 75 million arms in the US alone and generated USD 12 billion…
See our Cookie Privacy Policy Here
